Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactiplantibacillus plantarum ATCC 202195
- Development stage
- Unknown
- Lead developer
- International Flavors & Fragrances
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum ATCC-202195 (reclassified as Lactiplantibacillus plantarum ATCC 202195) is a live biotherapeutic probiotic strain developed for the prevention of neonatal sepsis and other infections in newborns. Originally isolated from the stool of a healthy infant, the strain is typically administered as a synbiotic in combination with the prebiotic fructooligosaccharide (FOS). Its mechanism of action involves colonizing the infant gut, strengthening the intestinal mucosal barrier, and modulating the neonatal immune system to prevent the translocation of pathogens into the systemic circulation. A landmark clinical trial in rural India, involving over 4,500 newborns and funded by the Bill & Melinda Gates Foundation, demonstrated that early administration of this synbiotic reduced the incidence of sepsis and respiratory tract infections by approximately 40%. International Flavors & Fragrances (IFF) is the primary manufacturer and commercial supplier of the strain.
- Brand names
- PPLP-217PPLP217PPLP 217
- Other names
- Lactobacillus plantarum ATCC-202195L. plantarum ATCC 202195
Beyond the preview
Go deeper on lactiplantibacillus plantarum ATCC 202195.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactiplantibacillus plantarum ATCC 202195.